China Starch Holdings Limited Overview
| Metric | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
| Full-time staff (period end) | 2,209 | 2,201 | 2,177 |
| Total staff costs incl. directors (RMB M) | 283.7 | 301.3 | 162.2 |
China Starch Holdings is a mid-sized, vertically integrated corn wet-miller and fermentation producer based in Shandong. It converts about 3–4 million tonnes of corn kernel a year into native cornstarch, by-products, and value-added derivatives. Its main derivatives are feed-grade lysine, starch-based sweeteners, modified starch and an emerging biobased-materials line (lactic acid and lactide/PLA trial lines). Revenue was RMB10.06bn in FY2025.
Two-thirds of revenue comes from commoditised upstream starch at low single-digit gross margins. Most profit comes from fermented products, chiefly lysine, which depends on the hog cycle and is now hit by EU, U.S. and other anti-dumping regimes.
The group's distinguishing traits are a net-cash balance sheet, about 34% insider control, a long history of uninterrupted final dividends, and a capital-light record. It is spending about RMB1.05bn on a Linqing cornstarch rebuild and an on-site thermal power plant to lower unit costs in an industry consolidating around scale. It swung to a first-half loss in H1 2026.
Company's own description (Annual Report 2025, Directors' Report)
The Company is an investment holding company. Its subsidiaries are principally engaged in the manufacture and sale of cornstarch, lysine, starch-based sweetener, modified starch and ancillary corn-based and corn-refined products. Revenue comes from two business segments, (i) upstream products and (ii) fermented and downstream products. All production is carried out in the PRC.
Independent characterisation
China Starch is a classic corn-refining "spread business." It buys corn kernel on the spot market and has not hedged in any year from FY2021 to H1 2026. Corn kernel and utilities make up about 97% of cost of sales (FY2025: cost of inventories RMB8,196m plus utilities RMB1,012m, against total cost of sales of RMB9,518m). Margins are therefore set by the spread between corn and the realised price of starch, lysine and co-products, not by pricing power.
The value chain is integrated:
-
Wet milling. Corn is steeped and milled into starch and co-products: corn gluten meal, corn germ, corn fibre/bran and corn steep liquor.
-
Captive feedstock. Part of the starch moves inter-segment into fermentation and conversion. Inter-segment sales were RMB2,006m in FY2025, up from RMB220m in FY2021. That rise reflects the 2023 lysine capacity expansion, which now consumes a much larger share of captive starch.
-
Fermentation and conversion. Captive starch becomes lysine (feed amino acid), liquid and crystallised starch sweeteners (glucose and maltose syrups), modified starches, and lactic acid and biobased materials.
Revenue model. The business is 100% product sales, recognised at a point in time (FY2025 note 2). There is no service, subscription or licensing revenue. Contracts are short (under one year). Customer credit runs 0–150 days, but receivables are tiny: 13 debtor days in FY2025, and most are bank acceptance bills.
Customer types and end-markets:
Animal feed: Lysine, corn gluten meal, corn fibre and germ meal. This is the largest profit pool and follows the PRC hog cycle.
Food and beverage: Native and modified starch, liquid sweeteners for drinks, confectionery and baking.
Industrial: Paper, textile, chemical, fermentation and pharmaceutical customers. Management has also targeted battery manufacturing as a new outlet for starch sugars (FY2023 MD&A).
Biobased materials: Lactic acid and lactide/PLA for biodegradable plastics. This is a niche and still sub-scale.
Export: 4.5% of FY2025 revenue (RMB449m), mostly lysine and cornstarch. Export share is shrinking under trade remedies.
Value-chain position. The group sits midstream: between grain growers and traders upstream, and feed mills, food and beverage manufacturers and industrial users downstream. It has no branded consumer business. Its competitive levers are scale, energy cost (steam and electricity), yield and logistics. The Linqing thermal power plant is a direct play on the energy lever.
Strategy
Stated strategy themes (management's words paraphrased; FY2025 and H1 2026 MD&A)
-
Scale and cost leadership in a consolidating industry. Management expects players who fail to expand capacity and adopt advanced technology to lose share gradually. It sees this consolidation continuing for the foreseeable future.
-
Expand the domestic distribution network and use economies of scale. This is reinforced in H1 2026 by redirecting lysine and sweetener sales to domestic customers.
-
Efficiency enhancement and cost optimisation in a low-margin, oversupplied environment (H1 2026 priority #1).
-
Prudent capital allocation. Stay cautious on future expansion and avoid products subject to capacity gluts (H1 2026 priority #2). This is a notable pivot from the 2022–2023 growth agenda (lysine, PLA, JV).
-
Shareholder returns via buybacks. Management states the 154m-share repurchase aims to lift EPS once the market recovers.
-
Energy self-sufficiency. The on-site thermal power plant at Linqing is meant to stabilise steam and electricity supply and cut cost.
Initiative register (last 24 months)
| Initiative | Announced | Investment | Funding | Target / status |
|---|---|---|---|---|
| Linqing Cornstarch Production Project (demolish and rebuild; 1.0Mt to 1.55Mt) | 20 Feb 2025 | RMB620m | Internal resources | Original target: operational June 2026. Revised: trial operation by end-2026 (H1 2026). |
| Linqing Thermal Power Project (dual-boiler, high-efficiency turbine generator) | 20 Feb 2025 | RMB428.7m | Internal resources and bank borrowings | Construction about 30 Jan 2026 to 31 Mar 2027. Commissioning Q1 2027. |
| Construction contract (facilities) with Juneng Construction | 25 May 2025 | RMB80m | Internal | Approved at EGM 9 Oct 2025 (99.99%) |
| Thermal plant construction contract with Juneng Construction | 19 Nov 2025 | RMB70m (after a 14% rebate) | Internal | Connected transaction requiring independent shareholder approval. |
| Lactic acid esters JV (Musashino) | Initiated 2020 | Budget n/d | — | Land acquired Feb 2026. Under feasibility reappraisal (Aug 2026). |
| Share buyback programme | 2,026 | About HK$25.96m (154m shares) | Cash | Done; shares cancelled 3 Aug 2026 |
| Biobased materials channel expansion | 2,026 | — | Opex | Volume up YoY in H1 2026; margins down |
Medium-term financial targets: none disclosed. The company does not publish guidance.
ESG commitments: no quantified targets in the sources retrieved.
Products & Services
No product is sold under a disclosed consumer brand. Products are sold as specification-grade commodities. Pricing is spot or short-contract and is not published beyond the realised ASPs below.
Installed capacity (end-2023, FY2023 Results — latest full table disclosed)
| Product | Annual capacity (tonnes) |
|---|---|
| Cornstarch | 2,700,000 |
| Lysine | 500,000 |
| Starch-based sweetener (crystallised) | 150,000 |
| Modified starch | 100,000 |
| D-lactic acid | 20,000 |
| Lactide / polylactide trial lines | 5,000 each (planned; trial use, excluded from the table above) |
Post-project: the Linqing cornstarch line is being rebuilt from 1.0Mt to 1.55Mt, with trial operation expected by end-2026. That implies group cornstarch capacity of about 3.25Mt (derived, assuming no other changes).
Upstream products segment
| Product | Description and specification | Target customer | Notes |
|---|---|---|---|
| Native cornstarch | Core wet-milled product; flagship by volume | Food processors, paper, textile, pharma, fermentation and chemical industries | Volume 1,698,626t in FY2025; ASP RMB2,472/t |
| Corn gluten meal | High-protein feed ingredient from wet milling | Feed mills | Price linked to soybean meal (FY2022 MD&A) |
| Corn germ | Oil-bearing germ for corn oil crushing | Edible oil crushers | Price linked to soybean oil (FY2022 MD&A) |
| Corn fibre / bran | Fibre feed ingredient | Feed mills | Demand tied to the breeding cycle |
| Corn steep liquor (slurry) | Nutrient-rich steep water | Fermentation and feed | Volumes and prices n/d |
Fermented and downstream products segment
| Product | Description and specification | Target customer | Latest data |
|---|---|---|---|
| Lysine | Essential amino acid feed additive; the group offers "different purity grades" as a one-stop lysine supplier (FY2022 MD&A). Grade split n/d. | Feed compounders (swine and poultry), domestic and export | FY2025 volume 561,447t; derived ASP about RMB5,206/t. H1 2026: 299,605t at RMB4,607/t. |
| Starch-based sweetener (liquid) | Glucose and maltose syrups; less energy-intensive than crystallised, as no crystallisation step is needed | Beverage, confectionery, food; trial outreach to battery manufacturing (FY2023) | 77.8% of sweetener volume in FY2025 |
| Starch-based sweetener (crystallised) | Crystalline dextrose/glucose; capacity 150kt | Food, pharma | 22.2% of sweetener volume in FY2025 |
| Modified starch | Chemically or physically modified starches, including "liquid modified starch," developed to get around dehydration and sewage constraints (FY2023) | Paper, food, textile | FY2025 volume 64,573t (FY2024: 113,023t). Output limited by sewage-control measures. |
| Biobased materials (D-lactic acid) | 20,000 tpa line; trial run 2022, normal operation Dec 2022 | Biodegradable plastics, chemicals | Included in "Others": RMB166.6m in FY2025 |
| Lactide / PLA (trial) | Trial lines completed end-2023 for product development | Bioplastics | Commercial output n/d |
| Lactic acid esters (JV, planned) | Shouguang Juneng Musashino Biotechnology with Musashino Chemical Laboratory. Original 2022 target: 20,000 tpa by end-2024. | Solvents and chemicals | Land bought Feb 2026; project "under further appraisal" (H1 2026) |
| Other (per aggregator profiles) | Dextrin, food-grade enzymes, food additives | Food industry | — |
Volume and realised price history
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cornstarch sales volume (tonnes) | 1,915,794 | 1,953,563 | 2,007,204 | 1,840,148 | 1,698,626 |
| Cornstarch ASP (RMB per tonne) | 2,988 | 2,872 | 2,816 | 2,626 | 2,472 |
| Lysine sales volume (tonnes) | 320,638 | 314,179 | 340,746 | 578,095 | 561,447 |
| Lysine ASP (RMB per tonne; FY2024–25 derived) | 6,937 | 7,718 | 6,638 | 5,929 | 5,206 |
| Sweetener sales volume (tonnes) | 196,049 | 237,718 | 179,598 | 217,581 | 216,978 |
| Sweetener ASP (RMB per tonne) | 2,650 | 2,277 | 2,629 | 2,301 | 2,046 |
| Average corn kernel cost (RMB per tonne, net of VAT) | 2,542 | 2,550 | 2,543 | 2,071 | 2,082 |
| Liquid sweetener share of sweetener volume (%) | 69.4 | 72.9 | — | 76.6 | 77.8 |
Note: The FY2023 liquid sweetener share is n/d. Modified starch volume is disclosed only for FY2024 (113,023t) and FY2025 (64,573t).
H1 2026 corn cost: RMB2,175/t (H1 2025: RMB2,068/t).
Financial Narrative
All figures are RMB millions from audited annual results announcements unless noted. EBITDA is derived as reported operating profit plus D&A.
Income statement
There are no dilutive instruments: no share options have been granted under the Share Option Scheme (FY2025).
Margins and growth (derived)
Revenue CAGR (derived): FY2021–FY2025 is −3.6% a year. FY2020–FY2025, from RMB8,892.3m, is +2.5% a year.
Balance sheet (31 December)
Notes:
-
The FY2025 intangible asset of RMB75.5m is a newly recognised item. Cash flow shows RMB24.4m spent on intangibles, and a prepayment for a construction project of RMB47.2m was reclassified. Its nature is not described in the extracts reviewed.
-
Long-term borrowings in FY2024–25 are a HK$-denominated loan from the controlling shareholder at a fixed 0.5% p.a. (RMB60.5m at FY2025). In FY2022–23 the shareholder loan sat within current borrowings at a floating rate.
-
All bank borrowings are short-term, RMB-denominated and fixed-rate.
H1 2026: total assets RMB7,121.9m; cash RMB1,986.8m; pledged deposits RMB478.5m; borrowings RMB1,282.3m (current RMB1,158.5m, non-current RMB123.8m); total equity RMB4,534.5m.
Cash flow
Notes:
-
Dividends paid in the S&P data exceed the company's dividends to owners (FY2022: RMB34.9m to owners vs RMB138.4m total). The difference is very likely dividends to non-controlling interests at non-wholly-owned subsidiaries.
-
The company's FY2024 results announcement records no buyback in FY2024. The S&P figure of RMB0.55m may reflect settlement timing of late-2023 trades.
Ratios
Ratio methodology:
-
FY2021 ROE, ROA and asset turnover use year-end balances.
-
ROIC = operating profit × (1 − 25%) ÷ (total equity + borrowings − cash), at year-end.
-
Turnover days, current and quick ratios, gearing and TSR are company-reported.
Commentary on trends, inflections and drivers
Revenue. Revenue peaked at RMB11.95bn in FY2022 and has fallen for three straight years, to RMB10.06bn in FY2025. Volume did not drive most of this decline. Cornstarch ASP fell 17% from RMB2,988/t (FY2021) to RMB2,472/t (FY2025). Lysine ASP fell about 33% from its RMB7,718/t peak in FY2022 to about RMB5,206/t in FY2025, and dropped further to RMB4,607/t in H1 2026.
Lysine volume grew about 70% in FY2024 after the capacity expansion, but this only partly offset price compression. The FY2025 decline also reflects a deliberate capacity cut: one Linqing cornstarch line was demolished for the rebuild, and cornstarch volume fell 7.7%.
Profitability is a corn-spread story. FY2024's record attributable profit of RMB482.3m came from a 19% drop in corn cost, from RMB2,543/t to RMB2,071/t, which management itself called unsustainable. FY2025 corn cost was roughly flat at RMB2,082/t, but product prices fell. Gross margin halved to 5.4%.
In H1 2026, corn rose 5.2% to RMB2,175/t while lysine ASP fell 18.4%. Gross margin compressed to 2.7% and the operating result turned to a loss of RMB55.4m. Without hedging, the group has full earnings exposure to the corn basis.
R&D collapse. Research expenses fell 86% from RMB324.1m (FY2022) to RMB46.8m (FY2025). Management attributes this to fewer projects. Part of the FY2024 profit recovery is therefore lower discretionary spending, not just better spreads.
Other income quality. Amortisation of government grants contributed RMB62.9m–RMB81.8m a year in FY2021–FY2025. It fell to RMB6.7m in H1 2026 because certain grants were fully amortised in 2025. This is a structural loss of about RMB60–70m in annual pre-tax income from FY2026.
Balance sheet and cash. The group has been net cash every year. Gross borrowings rose sharply in FY2024 to RMB1.48bn, alongside pledged deposits of RMB1.16bn. This is consistent with bill and deposit arbitrage: borrowing short-term at low fixed rates against pledged deposits, which explains rising finance income (RMB49.3m in FY2025). True economic leverage is negligible.
Free cash flow is volatile and working-capital driven. It was negative in FY2023 and FY2025. Capex is rising with the RMB1.05bn Linqing programme.
Returns. ROE averaged about 8% over five years but swings from 3% to 12% with the corn cycle. It was −0.55% on a trailing basis by mid-2026 (S&P).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products |
|---|---|---|
Upstream products | Manufacture and sale of cornstarch and ancillary corn-refined products | Native cornstarch, corn gluten meal, corn germ, corn fibre/bran, corn steep liquor (slurry) |
Fermented and downstream products | Manufacture and sale of lysine, starch-based sweetener, modified starch and other products | Lysine (several purity grades), liquid and crystallised starch sweeteners, modified starch (incl. liquid modified starch), biobased materials (lactic acid and related), other fermented products |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Upstream products revenue (CNY Mn) | 8,576.5 | 8,706.0 | 8,596.9 | 7,007.9 | 6,313.4 |
Fermented and downstream revenue (CNY Mn) | 3,062.8 | 3,242.9 | 3,200.7 | 4,407.9 | 3,745.1 |
Total revenue (CNY Mn) | 11,639.3 | 11,948.9 | 11,797.5 | 11,415.8 | 10,058.5 |
Inter-segment sales, upstream (CNY Mn) | 220.1 | 1,485.9 | 1,603.7 | 2,249.3 | 2,006.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Upstream gross profit (CNY Mn) | 496.4 | 441.7 | 130.0 | 429.3 | 172.5 |
Fermented and downstream gross profit (CNY Mn) | 455.9 | 748.8 | 426.6 | 733.9 | 368.4 |
Upstream reportable segment profit (CNY Mn) | 443.0 | 230.2 | -85.4 | 233.9 | 10.9 |
Fermented and downstream segment profit (CNY Mn) | 333.1 | 396.7 | 263.4 | 582.7 | 241.9 |
Upstream gross margin (%) | 5.8 | 5.1 | 1.5 | 6.1 | 2.7 |
Fermented and downstream gross margin (%) | 14.9 | 23.1 | 13.3 | 16.7 | 9.8 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Upstream revenue growth YoY (%) | 1.5 | -1.3 | -18.5 | -9.9 |
Fermented and downstream revenue growth YoY (%) | 5.9 | -1.3 | 37.7 | -15.0 |
Upstream share of revenue (%) | 72.9 | 72.9 | 61.4 | 62.8 |
Fermented and downstream share of revenue (%) | 27.1 | 27.1 | 38.6 | 37.2 |
Products
| Product | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Lysine (CNY Mn) | 2,224.2 | 2,424.7 | 2,261.8 | 3,427.6 | 2,922.9 |
Starch-based sweetener (CNY Mn) | 519.5 | 541.4 | 472.2 | 500.6 | 444.0 |
Modified starch (CNY Mn) | 267.5 | 196.0 | 351.6 | 374.6 | 211.7 |
Others incl. biobased materials (CNY Mn) | 51.6 | 80.8 | 115.1 | 105.1 | 166.6 |
Results by Segment and Segment Margins & Growth (%) (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Upstream revenue (CNY Mn) | 3,149.7 | 3,191.4 |
Upstream gross profit (CNY Mn) | 91.5 | 78.7 |
Upstream gross margin (%) | 2.9 | 2.5 |
Upstream segment result (CNY Mn) | 5.6 | -32.3 |
Fermented and downstream revenue (CNY Mn) | 1,965.1 | 1,831.0 |
Fermented and downstream gross profit (CNY Mn) | 337.3 | 55.0 |
Fermented and downstream gross margin (%) | 17.2 | 3.0 |
Fermented and downstream segment result (CNY Mn) | 295.1 | 9.2 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 11,639.3 | 11,948.9 | 11,797.5 | 11,415.8 | 10,058.5 |
Cost of sales (CNY Mn) | 10,687.1 | 10,758.4 | 11,241.0 | 10,252.5 | 9,517.5 |
Gross profit (CNY Mn) | 952.2 | 1,190.5 | 556.6 | 1,163.2 | 540.9 |
Distribution expenses (CNY Mn) | 164.9 | 171.0 | 157.2 | 157.9 | 124.3 |
Administrative expenses (CNY Mn) | 192.0 | 207.8 | 194.6 | 217.3 | 227.7 |
Research expenses (CNY Mn) | 199.6 | 324.1 | 160.5 | 89.7 | 46.8 |
Other net income (CNY Mn) | 114.9 | 119.8 | 113.1 | 117.6 | 121.6 |
Operating profit (CNY Mn) | 510.5 | 607.3 | 157.5 | 815.9 | 263.9 |
D&A (CNY Mn) | 259.3 | 284.8 | 277.4 | 285.5 | 276.2 |
EBITDA, derived (CNY Mn) | 769.8 | 892.1 | 434.8 | 1,101.4 | 540.0 |
Finance income (CNY Mn) | 8.1 | 18.3 | 24.1 | 31.0 | 49.3 |
Finance expenses (CNY Mn) | 7.1 | 4.5 | 4.8 | 8.8 | 11.2 |
Profit before tax (CNY Mn) | 511.5 | 621.1 | 176.8 | 838.1 | 302.0 |
Income tax (CNY Mn) | 108.7 | 125.7 | 19.4 | 212.6 | 64.6 |
Profit for the year (CNY Mn) | 402.8 | 495.4 | 157.4 | 625.6 | 237.4 |
Profit attributable to owners (CNY Mn) | 345.6 | 352.0 | 108.0 | 482.3 | 184.9 |
Non-controlling interests (CNY Mn) | 57.2 | 143.4 | 49.4 | 143.3 | 52.4 |
Basic EPS (MYR Bn) | 0.0577 | 0.0587 | 0.0180 | 0.0808 | 0.0310 |
Diluted EPS (MYR Bn) | 0.0577 | 0.0587 | 0.0180 | 0.0808 | 0.0310 |
Final DPS (HK cents) | 0.69 | 0.69 | 0.69 | 0.98 | 0.98 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 30.9 | 2.7 | -1.3 | -3.2 | -11.9 |
Gross margin (%) | 8.2 | 10.0 | 4.7 | 10.2 | 5.4 |
Operating margin (%) | 4.4 | 5.1 | 1.3 | 7.1 | 2.6 |
EBITDA margin (%) | 6.6 | 7.5 | 3.7 | 9.6 | 5.4 |
Net margin, attributable (%) | 3.0 | 2.9 | 0.9 | 4.2 | 1.8 |
Effective tax rate (%) | 21.2 | 20.2 | 11.0 | 25.4 | 21.4 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 4,719.2 | 5,105.8 | 5,352.6 | 6,958.9 | 6,822.8 |
Property, plant and equipment (CNY Mn) | 2,004.3 | 1,892.1 | 2,162.5 | 2,014.0 | 2,046.6 |
Right-of-use assets (CNY Mn) | 447.2 | 436.3 | 425.9 | 415.6 | 418.0 |
Intangible assets incl. goodwill (CNY Mn) | 0 | 0 | 0 | 0 | 75.5 |
Inventories (CNY Mn) | 602.3 | 866.4 | 730.7 | 611.1 | 772.0 |
Cash and cash equivalents (CNY Mn) | 1,001.0 | 1,003.0 | 899.8 | 2,209.9 | 1,858.6 |
Pledged bank deposits (CNY Mn) | 0 | 207.6 | 500.1 | 1,160.1 | 995.6 |
Short-term borrowings (CNY Mn) | 108.2 | 285.9 | 559.4 | 1,420.3 | 1,020.0 |
Long-term borrowings (CNY Mn) | 3.0 | 0 | 0 | 59.3 | 60.5 |
Total borrowings (CNY Mn) | 111.2 | 285.9 | 559.4 | 1,479.6 | 1,080.5 |
Net debt, excl. pledged deposits (CNY Mn; negative = net cash) | -889.8 | -717.1 | -340.5 | -730.3 | -778.0 |
Net debt, incl. pledged deposits (CNY Mn) | -889.8 | -924.7 | -840.5 | -1,890.4 | -1,773.7 |
Equity attributable to owners (CNY Mn) | 3,278.0 | 3,595.1 | 3,661.8 | 4,106.0 | 4,237.6 |
Total equity (CNY Mn) | 3,492.0 | 3,821.8 | 3,936.6 | 4,493.7 | 4,650.7 |
Current assets (CNY Mn) | 2,197.6 | 2,666.5 | 2,697.6 | 4,419.4 | 4,135.9 |
Current liabilities (CNY Mn) | 894.2 | 965.9 | 1,192.4 | 2,158.6 | 1,928.8 |
Working capital (CNY Mn) | 1,303.5 | 1,700.6 | 1,505.3 | 2,260.8 | 2,207.2 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 1,107.0 | 316.8 | 413.4 | 1,317.0 | 298.9 |
Capital expenditure (CNY Mn) | 394.9 | 211.1 | 421.6 | 255.0 | 338.2 |
Free cash flow (CNY Mn) | 712.0 | 105.7 | -8.3 | 1,062.0 | -39.3 |
Dividends paid (CNY Mn) | 44.9 | 138.4 | 66.9 | 67.9 | 80.3 |
Share buybacks (CNY Mn) | 0 | 0 | 3.1 | 0.6 | 0 |
Net debt issued / (repaid) (CNY Mn) | -15.5 | 172.9 | 273.4 | 919.0 | -397.6 |
Change in working capital (CNY Mn) | 446.1 | -344.1 | 67.6 | 356.2 | -96.2 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable, avg equity (%) | 10.5 | 10.2 | 3.0 | 12.4 | 4.4 |
ROA, profit for year / avg assets (%) | 8.5 | 10.1 | 3.0 | 10.2 | 3.4 |
ROIC, derived (%) | 14.7 | 14.7 | 3.3 | 16.3 | 5.1 |
Current ratio (x) | 2.5 | 2.8 | 2.3 | 2.0 | 2.1 |
Quick ratio (x) | 1.8 | 1.9 | 1.6 | 1.8 | 1.7 |
Gearing, borrowings / total assets (%) | 2.4 | 5.6 | 10.5 | 21.3 | 15.8 |
Debt / equity (%) | 3.2 | 7.5 | 14.2 | 32.9 | 23.2 |
Net debt / EBITDA (x) | -1.16 | -0.80 | -0.78 | -0.66 | -1.44 |
Interest coverage, operating profit / finance expense (x) | 71.9 | 135.8 | 33.1 | 92.3 | 23.6 |
Asset turnover (x) | 2.47 | 2.43 | 2.26 | 1.85 | 1.46 |
Debtor days | 14 | 11 | 12 | 12 | 13 |
Inventory days | 24 | 25 | 26 | 24 | 27 |
Creditor days | 7 | 7 | 5 | 5 | 10 |
Cash conversion cycle (days) | 31 | 29 | 33 | 31 | 30 |
Total shareholder return, company-reported (%) | 41.7 | 9.4 | -36.5 | 44.8 | -0.1 |
Revenue by Region and Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
PRC revenue (CNY Mn) | 10,811.0 | 11,493.6 | 10,856.9 | 10,702.5 | 9,609.7 |
Other countries revenue (CNY Mn) | 828.4 | 455.3 | 940.6 | 713.2 | 448.8 |
Overseas share of revenue (%) | 7.1 | 3.8 | 8.0 | 6.2 | 4.5 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
PRC growth YoY (%) | 6.3 | -5.5 | -1.4 | -10.2 |
Other countries growth YoY (%) | -45.0 | 106.6 | -24.2 | -37.1 |
Valuation Snapshot
| Metric | Value |
|---|---|
Share price (HKD) | 0.176 |
Market capitalisation (HKD Bn) | 1.03 |
Enterprise value (HKD Bn) | 0.67 |
52-week change (%) | -12.87 |
Beta (5Y) | 0.39 |
Average daily volume (20-day, shares) | 4,966,843 |
Trailing P/E (x) | 48.4 |
P/B (x) | 0.20 |
P/TBV (x) | 0.22 |
EV/Sales (x) | 0.06 |
EV/EBITDA, TTM (x) | 3.30 |
Dividend yield (%) | 6.0 |
Net cash (HKD Mn) | 798.6 |
Altman Z-score / Piotroski F-score | 2.5 / 1 |
Margin Analysis (%) — Total shareholder return
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total shareholder return (%) | 41.7 | 9.4 | -36.5 | 44.8 | -0.1 |
Capital Markets
| Metric | China Starch | Fufeng Group |
|---|---|---|
FY2025 net margin (%) | 1.8 | 8.8 |
FY2025 gross margin (%) | 5.4 | 19.7 |
P/B (x) | 0.20 | — |
Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Final DPS (HK cents) | 0.90 | 0.69 | 0.69 | 0.69 | 0.98 | 0.98 |
Interim DPS (HK cents) | 0 | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Payout ratio, final dividend / attributable profit (%, derived) | 10 | 11 | 35 | 11 | 29 |
Share Price & Returns
| Period | Shares repurchased (M) | Consideration (HKD Mn) | Price range (HKD) |
|---|---|---|---|
Aug–Dec 2023 | 25.565 | 3.375 | 0.127–0.145 |
FY2025 | 0 | 0 | — |
H1 2026 | 104.465 | 17.569 | 0.146–0.19 |
1–17 Jul 2026 | 49.535 | 8.389 | 0.155–0.178 |
Analyst Conclusions
Management guidance (H1 2026 Interim Results)
-
No numerical guidance.
-
Management expects H2 2026 to remain challenging, with no clear signs of a near-term recovery.
-
Priorities: efficiency, cost control and cautious capital allocation that avoids capacity-glut products.
-
Linqing trial operation by end-2026; thermal plant Q1 2027.
Consensus
Simply Wall St indicates 4 analysts cover the stock (May 2025). Their estimates and price targets are not publicly disclosed in the sources retrieved. Consensus growth expectations are n/d.
Bull case
-
Valuation floor. The stock trades at about 0.20x book (equity RMB4.16bn at 30 Jun 2026) with net cash including pledged deposits of about RMB1.18bn at H1 2026. Enterprise value of HK$0.67bn is about 3.3x trailing EBITDA. Mid-cycle profit like FY2022 (RMB352m) or FY2024 (RMB482m) would imply a very low multiple.
-
Cost-curve step-down from 2027. The rebuilt 1.55Mt Linqing line plus captive power targets the two biggest cost items, corn yield and utilities (RMB1.0bn a year). That could lift upstream margins above the 1.5%–6.1% historical range.
-
Cycle mean reversion plus consolidation. Lysine ASP (RMB4,607/t) is 40% below its FY2022 peak. Exits by weaker players and a hog-cycle upturn have historically produced sharp rebounds (FY2024 gross profit +109%). Ongoing buybacks amplify per-share recovery.
Bear case
-
Structural loss of export outlets. EU duties of 47.7%–58.3% and U.S. AD deposits of 142.59% keep Chinese lysine at home, entrenching domestic oversupply. China Starch has no differentiated amino acids to pivot to, unlike Meihua and Fufeng.
-
Earnings quality erodes. Grant amortisation (RMB60–80m a year) has largely ended, R&D has been cut to 0.47% of revenue, and the corn exposure is unhedged. Without a spread recovery, FY2026 could be the first full-year loss in the review period: H1 2026 already shows an attributable loss of RMB14.7m.
-
Capital allocation and governance discount. RMB1.05bn of capex is going into commoditised cornstarch, which management itself calls oversupplied. Execution runs through connected-party contractors. With about 64% control, minority shareholders have little influence and the discount to book may persist.
Catalysts and monitorables (next 12 months)
| Item | Timing |
|---|---|
| Linqing new cornstarch line trial operation | End-2026 |
| Thermal power plant commissioning | Q1 2027 |
| FY2026 profit warning / alert, if any | Feb 2027 (historical pattern) |
| FY2026 annual results and final dividend decision | Mar 2027 |
| EU lysine absorption investigation outcome (possible duty increase) | H2 2026 – 2027 |
| U.S. ITC final injury determination / AD-CVD orders on L-lysine | H2 2026 |
| Corn kernel price trajectory (state reserve buying, import policy) | Ongoing |
| PRC hog inventory and feed demand | Ongoing |
| Musashino JV go / no-go decision | Pending |
| Further buybacks under the AGM mandate | Ongoing |
Analyst verdict
China Starch Holdings is a well-capitalised but structurally low-return corn processor sitting at the bottom of a cyclical trough.
The five-year record shows the business as it is: revenue drifting from RMB11.6bn to RMB10.1bn and gross margins swinging between 4.7% and 10.2% with the corn spread. Attributable profit has ranged from RMB108m to RMB482m with no visible structural uplift. The FY2024 peak came from cheap corn plus new lysine scale. It reversed within eighteen months as corn costs rose and export markets closed behind anti-dumping walls in the EU and U.S. By H1 2026, lysine gross margin had fallen from 17.2% to 3.0% and the group recorded an interim loss.
Against this, the balance sheet is unusually strong for the sector. Cash and pledged deposits exceed borrowings by about RMB1.2bn, book equity is about RMB4.2bn, and the market values the whole company at about HK$1.0bn. Management is using that strength to rebuild Linqing at larger scale with captive power, and to retire shares at about a fifth of book value. Both actions make sense in a consolidating industry where survivors with cost advantages should gain share.
The key unknowns are timing and returns. Commissioning at end-2026 and Q1 2027 means cost benefits will not show until FY2027 results. Grant income has rolled off. Domestic oversupply is being worsened by trade diversion that China Starch cannot control. The company also lacks the higher-value amino acid portfolio that protects larger peers such as Fufeng (19.7% gross margin in FY2025).
Verdict: The stock offers deep value and optionality on a corn and lysine recovery, backed by downside protection from net cash and a stable final dividend. It is not a compounding franchise. Investors should treat it as a cyclical, book-value-anchored position, monitor the Linqing ramp-up and FY2026 dividend decision closely, and size it with the governance and trade-policy discounts in mind.
Data limitations: - Peer figures are limited to verified disclosures.
- All derived metrics are labelled as such.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Age / birth year | Background (as disclosed) |
|---|---|---|---|---|
Tian Qixiang | Executive Chairman | Chairman since listing (named in the 2007 Annual Report) | Born 1964 (Yahoo) | Founder-chairman. Did not attend the 2022–2026 AGMs, a recurring Corporate Governance Code deviation. Further profile in AR2025 (pp. |
Gao Shijun | CEO and Executive Director | CEO since 7 Dec 2009 (MarketScreener; another source says 2011) | Born 1968 | Undergraduate, Shandong University (1989); MBA, Shandong University (2012). Director and GM of Golden Corn; director of DGC, Golden Far East Modified Starch, Golden Corn Biotechnology and the Musashino JV. Former member, China Starch Industry Association. |
Yu Yingquan | Executive Director | — | Born 1969 | — |
Liu Xianggang | Executive Director | — | Born 1969 | — |
Prof. Chen Zhijun | INED | Appointed 15 Oct 2025 | — | n/d in sources retrieved |
Prof. Gao Qunyu | INED; Chair of Remuneration Committee; member of Audit and Nomination Committees | Effective from 12 May 2026 AGM, 3-year term; fee RMB50,000 a year | 60 | Professor and doctoral supervisor, South China University of Technology (since 2008). BSc, MSc and PhD in sugar engineering (SCUT). Vice Chairman, China Starch Industry Association. Deputy Director, National Technical Committee for Standardization of Edible Starch and Starch Derivatives. Editorial board of Carbohydrate Polymers. |
Ms. Sze Tak On | INED | n/d (on the board by FY2025) | — | — |
Leung Siu Hong | Company Secretary | — | Born 1976 | FCCA, FCIS, FCPA, FCS |
Board & Management Changes
| Date | Change |
|---|---|
Between 20 Mar 2024 and early 2025 | Mr. Yue Kwai Wa, Ken ceased to be an INED. Exact date n/d; Ms. Sze Tak On appears to be his successor. |
15 Oct 2025 | Mr. Sun Mingdao retired as INED; Prof. Chen Zhijun appointed |
12 May 2026 | Prof. Hua Qiang retired after 9 years as INED (previously Remuneration Committee Chair); Prof. Gao Qunyu appointed |
Directors' Remuneration
| Executive | Total pay FY2023 (USD K) |
|---|---|
Tian Qixiang | 66.16 |
Gao Shijun | 75.40 |
Yu Yingquan | 56.52 |
Liu Xianggang | 56.52 |
Major Shareholders
| Holder | Shares (M) | Stake (%) | Source / date |
|---|---|---|---|
Merry Boom Group Limited (controlling shareholder) | 3,705.4 | 62.1 | Simply Wall St, May 2025 (on 5,964.5m shares) |
Merry Boom Group Limited, pro forma | 3,705.4 | 63.8 | Derived on about 5,810.5m shares after Aug 2026 cancellation |
Dimensional Fund Advisors LP | 33.0 | 0.55 | Simply Wall St, May 2025 |
Tareno International Asset Managers | 13.7 | 0.23 | Simply Wall St |
Polunin Capital Partners | 3.3 | 0.06 | Simply Wall St |
Acadian Asset Management | 2.6 | 0.04 | Simply Wall St |
American Century Investment Management | 1.9 | 0.03 | Simply Wall St |
Primorski Skladi | 1.4 | 0.02 | Simply Wall St |
Total institutions | 55.9 | 0.94 | Simply Wall St |
General public | 2,203.2 | 36.9 | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing | Positioning vs China Starch |
|---|---|---|---|
Lysine / amino acids | Meihua Holdings Group | 600873.SS | Global leader in MSG and lysine; 2025 revenue RMB24.21bn; bought Kyowa Hakko's amino acid business in 2025; lowest EU duty (47.7%) |
Lysine / amino acids | Fufeng Group | 0546.HK | 2025 revenue RMB27.88bn; lysine volume 435,140t (+30.4%); gross margin 19.7% |
Lysine / amino acids | Inner Mongolia Eppen Biotech | Private | Large lysine exporter; EU duty 58.2%; received an individual U.S. rate |
Lysine / amino acids | CJ CheilJedang (Bio) | 097950.KS | Global lysine leader; U.S. AD petitioner via CJ Bio America |
Lysine / amino acids | Archer Daniels Midland | ADM (NYSE) | U.S. lysine producer; AD petitioner |
Lysine / amino acids | Eurolysine (Avril Group) | Private | Sole EU lysine producer; EU AD complainant |
Cornstarch / sweeteners | COFCO Biotechnology | 000930.SZ | State-backed corn processing and fuel ethanol |
Cornstarch / sweeteners | Global Bio-chem Technology / Global Sweeteners | 0809.HK / 3889.HK | Northeast China corn refiners; much reduced scale |
Cornstarch / co-products | Jinhe Biotechnology | 002688.SZ | Starch and co-products alongside feed antibiotics |
Cornstarch / co-products | Shandong Ensign Industry | 300183.SZ (verify) | Shandong cornstarch producer; listed by CNChemicals as a peer |
Cornstarch / co-products | Zhucheng Xingmao Corn Developing | Private | Large Shandong cornstarch and sweetener producer |
Global starch | Cargill, Ingredion, Roquette, Tate & Lyle | Various | Global specialty starch leaders; limited direct PRC commodity overlap |
Peer Comparison FY2025
| Metric | China Starch | Fufeng Group | Meihua Holdings |
|---|---|---|---|
Revenue FY2025 (CNY Mn) | 10,058.5 | 27,879 | 24,209 |
Revenue growth FY2025 (%) | -11.9 | 0.4 | -3.4 |
Gross margin FY2025 (%) | 5.4 | 19.7 | — |
Net margin FY2025 (%) | 1.8 | 8.8 | 13.6 |
Net profit FY2025 (CNY Mn) | 184.9 | 2,465 | 3,281 |
R&D % of revenue | 0.47 | — | — |
Recent Developments
--



